Iptakalim inhibited endothelin-1-induced proliferation of human pulmonary arterial smooth muscle cells through the activation of KATP channel

Vascular Pharmacology

Volumn 48, Issue 2-3, 2008, Pages 92-99

  Zhu, Yuming ^a   Zhang, Shijiang ^a   Xie, Weiping ^a   Li, Qingling ^a   Zhou, Yanjuan ^a   Wang, Hong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

ATP sensitive K+ channels; Endothelin 1; Human pulmonary arterial smooth muscle cells; Iptakalim; Mitogen activated protein kinases

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM; ENDOTHELIN 1; GLIBENCLAMIDE; IPTAKALIM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PINACIDIL; PROPIDIUM IODIDE; THYMIDINE;

ARTERY MUSCLE; ARTICLE; CELL CYCLE PHASE; CELL PROLIFERATION; CYTOSOL; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; SMOOTH MUSCLE FIBER; STAINING; WESTERN BLOTTING;

ANTIHYPERTENSIVE AGENTS; BLOTTING, WESTERN; CALCIUM; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; FLOW CYTOMETRY; GLYBURIDE; HUMANS; KATP CHANNELS; MEMBRANE TRANSPORT MODULATORS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PINACIDIL; POTASSIUM CHANNEL BLOCKERS; PROPYLAMINES; PULMONARY ARTERY;

EID: 40149089375     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2008.01.001     Document Type: Article

References (37)

1. Agapitov A.V., and Haynes W.G. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 3 (2002) 1-15
2. + channel functional impairment after brain injury. J. Neurotrauma 18 (2001) 1039-1048
3. ATP channels in vascular smooth muscle. Clin. Exp. Pharmacol. Physiol. 29 (2002) 312-316
4. Budhiraja R., Tuder R.M., and Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 109 (2004) 159-165
5. Chen Y.F., and Oparil S. Endothelin and pulmonary hypertension. J. Cardiovasc. Pharmacol. 35 (2000) S49-S53
6. Choi J., and Husain M. Calmodulin-mediated cell cycle regulation: new mechanisms for old observations. Cell Cycle 5 (2006) 2183-2186
7. + channels regulate resting potential of pulmonary arterial smooth muscle cells. Am. J. Physiol. 262 (1992) H916-H920
8. + channels of vascular smooth muscle cells. J. Cardiovasc. Electrophysiol. 14 (2003) 94-103
9. Cui Y., Tran S., Tinker A., and Clapp L.H. The molecular composition of K(ATP) channels in human pulmonary artery smooth muscle cells and their modulation by growth. Am. J. Respir. Cell Mol. Biol. 26 (2002) 135-143
10. Daou G.B., and Srivastava A.K. Reactive oxygen species mediate Endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells. Free Radic. Biol. Med. 37 (2004) 208-215
11. Force T., and Bonventre J.V. Growth factors and mitogen-activated protein kinases. Hypertension 31 (1998) 152-161
12. Galie N., Manes A., and Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 61 (2004) 227-237
13. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., and Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353 (2005) 2148-2157
14. Goirand F., Bardou M., Guerard P., Dumas J.P., Rochette L., and Dumas M. ETA, mixed ETA/ETB receptor antagonists, and protein kinase C inhibitor prevent acute hypoxic pulmonary vasoconstriction: influence of potassium channels. J. Cardiovasc. Pharmacol. 41 (2003) 117-125
15. Humbert M., Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M., Christman B.W., Weir E.K., Eickelberg O., Voelkel N.F., and Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43 (2004) 13S-24S
16. Kahl C.R., and Means A.R. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr. Rev. 24 (2003) 719-736
17. 2+, calmodulin, and cyclins in vascular smooth muscle cell cycle. Circ. Res. 98 (2006) 1240-1243
18. + channels in pulmonary hypertension. Vasc. Pharmacol. 38 (2002) 25-33
19. McLaughlin V.V., Gaine S.P., Barst R.J., Oudiz R.J., Bourge R.C., Frost A., Robbins I.M., Tapson V.F., McGoon M.D., Badesch D.B., Sigman J., Roscigno R., Blackburn S.D., Arneson C., Rubin L.J., and Rich S. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J. Cardiovasc. Pharmacol. 41 (2003) 293-299
20. McLaughlin V.V., Sitbon O., Badesch D.B., Barst R.J., Black C., Galie N., Rainisio M., Simonneau G., and Rubin L.J. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. 25 (2005) 244-249
21. Michel R.P., Langleben D., and Dupuis J. The endothelin system in pulmonary hypertension. Can. J. Physiol. Pharm. 81 (2003) 542-554
22. + channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation 13 (2006) 615-632
23. + channels. Nature 344 (1990) 770-773
24. ATP channels in rabbit coronary and pulmonary arterial smooth muscle cells. J. Cardiovasc. Pharmacol. 45 (2005) 99-108
25. Platoshyn O., Golovina V.A., Bailey C.L., Limsuwan A., Krick S., Juhaszova M., Seiden J.E., Rubin L.J., and Yuan J.X. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am. J. Physiol., Cell. Physiol. 279 (2000) C1540-C1549
26. Ram C.V. Possible therapeutic role of endothelin antagonists in cardiovascular disease. Am. J. Ther. 10 (2003) 396-400
27. Robinson M.J., and Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9 (1997) 180-186
28. Sato K., Morio Y., Morris K.G., Rodman D.M., and McMurtry I.F. Mechanism of hypoxic pulmonary vasoconstriction involves ET(A) receptor-mediated inhibition of K(ATP) channel. Am. J. Physiol., Lung Cell. Mol. Physiol. 278 (2000) L434-L442
29. + channels. Prog. Biophys. Mol. Biol. 81 (2003) 133-176
30. Shimoda L.A., Sylvester J.T., Booth G.M., Shimoda T.H., Meeker S., Undem B.J., and Sham J.S. Inhibition of voltage-gated K(+) currents by endothelin-1 in human pulmonary arterial myocytes. Am. J. Physiol., Lung Cell. Mol. Physiol. 281 (2001) L1115-L1122
31. + channels in arterial smooth muscle. Science 245 (1989) 177-180
32. Wang H. Pharmacological characteristics of the novel antihypertensive drug iptakalim hydrochloride and its molecular mechanisms. Drug Dev. Res. 58 (2003) 65-68
33. Wanstall J.C., Kay C.S., and O'Donnell S.R. Pinacidil-induced relaxation in pulmonary arteries isolated from pulmonary hypertensive and normotensive rats and pre-contracted with different spasmogens. Pulm. Pharmacol. 7 (1994) 401-408
34. ATP channel opener, on pulmonary vascular remodeling in hypoxic rats. Life Sci. 75 (2004) 2065-2076
35. ATP channel opener, in cultured rabbit pulmonary arterial smooth muscle cells. Eur. J. Pharmacol. 511 (2005) 81-87
36. Yamboliev I.A., Hruby A., and Gerthoffer W.T. Endothelin-1 activates MAP kinases and c-Jun in pulmonary artery smooth muscle. Pulm. Pharmacol. Ther. 11 (1998) 205-208
37. Yoshizumi M., Kim S., Kagami S., Hamaguchi A., Tsuchiya K., Houchi H., Iwao H., Kido H., and Tamaki T. Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br. J. Pharmacol. 125 (1998) 1019-1027